Leukemia Research Reports最新文献_第2页

Targeting menin for precision therapy in high-risk acute myeloid leukemia 以 Menin 为靶点，对高风险急性髓性白血病进行精准治疗。

IF 0.7

Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2024.100495

Abdur Jamil , Zaheer Qureshi , Zain Mary El-amir , Gillian Kupakuwana-Suk , Hamzah Akram , Mohsin Ahmad , Eric Huselton

引用次数: 0

Case report: Rechallenge with gilteritinib after acute pancreatitis in FLT3-positive AML

IF 0.7

Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100503

Taner TAN , Genco Gençdal , Ümit Barbaros Üre , Olga Meltem AKAY

引用次数: 0

Management of hemolytic transfusion reactions in a patient with chronic myelomonocytic leukemia and rare antibodies: A case report 慢性髓单细胞白血病合并罕见抗体患者的溶血性输血反应的处理：1例报告

IF 0.7

Leukemia Research Reports Pub Date : 2024-11-28 DOI: 10.1016/j.lrr.2024.100485

Grace S. Park , Himachandana Atluri , Courtney D. DiNardo , Bryan Guillroy , Jean Horak , Effrosyni Apostolidou , Maryam Buni , Guillermo Montalban Bravo , Naveen Pemmaraju

引用次数: 0

Acute lower limb ischemia revealing hypo granular acute promyelocytic leukemia 急性下肢缺血显示低颗粒急性早幼粒细胞白血病

IF 0.7

Leukemia Research Reports Pub Date : 2024-11-25 DOI: 10.1016/j.lrr.2024.100488

Sabrina Belmahi , Zainab Kajeiou , Loubna Yacoubi , Noussaiba Azzi , Mounia Slaoui , Abdelilah Berhili , Mohammed Bensalah , Rachid Seddik

{"title":"Acute lower limb ischemia revealing hypo granular acute promyelocytic leukemia","authors":"Sabrina Belmahi , Zainab Kajeiou , Loubna Yacoubi , Noussaiba Azzi , Mounia Slaoui , Abdelilah Berhili , Mohammed Bensalah , Rachid Seddik","doi":"10.1016/j.lrr.2024.100488","DOIUrl":"10.1016/j.lrr.2024.100488","url":null,"abstract":"<div><h3>Introduction</h3><div>Acute promyelocytic leukemia (AML-M3), classified as acute Myeloid leukemia with PML RARA according to the 5th edition of the World Health Organization classification of haematolymphoid tumors 2022 [1], is marked by abnormal promyelocyte proliferation and is known for high risks of bleeding and thromboembolic complications. We present a case where lower limb ischemia revealed this leukemia in a child.</div></div><div><h3>Case report</h3><div>An 11-year-old with minor ankle trauma developed severe lower limb ischemia, leading to the discovery of subtotal femoral artery thrombosis. Blood tests revealed hyperleukocytosis, thrombocytopenia, and anemia with 88 % blasts, confirming acute myeloid leukemia (AML-M3). Karyotyping showed a t(15;17) translocation, and the child was started on emergency chemotherapy.</div></div><div><h3>Discussion</h3><div>Acute promyelocytic leukemia (APL), classified as AML-M3 with PML-RARA, is characterized by abnormal promyelocytes and accounts for about 10 % of acute leukemias, mostly in middle-aged adults. It has two variants: common hypergranular and rare hypogranular forms. APL can present with bone marrow failure, anemia, bleeding, and occasionally thromboembolic events, as seen in this case. The ischemia mechanism is not fully understood but may involve vessel obstruction by blasts or hypercoagulability. Diagnosis relies on clinical, morphological, phenotypic, and cytogenetic evidence, with treatment involving all-trans retinoic acid (ATRA) and arsenic trioxide (ATO).</div></div><div><h3>Conclusion</h3><div>Hypogranular acute promyelocytic leukemia (AML3v) is a rare form and is even rarer when it is discovered following an ischaemic event, which is what makes our case so special.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100488"},"PeriodicalIF":0.7,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Vietnamese patients diagnosed with myelodysplastic neoplasms: Practical experience in a developing country 越南骨髓增生异常肿瘤患者的治疗：在发展中国家的实践经验

IF 0.7

Leukemia Research Reports Pub Date : 2024-11-24 DOI: 10.1016/j.lrr.2024.100490

Quang Hao Nguyen , Minh Phuong Vu , Ha Trang Kieu , Duc Binh Vu , Ha Thanh Nguyen , Quoc Khanh Bach

{"title":"Treatment of Vietnamese patients diagnosed with myelodysplastic neoplasms: Practical experience in a developing country","authors":"Quang Hao Nguyen , Minh Phuong Vu , Ha Trang Kieu , Duc Binh Vu , Ha Thanh Nguyen , Quoc Khanh Bach","doi":"10.1016/j.lrr.2024.100490","DOIUrl":"10.1016/j.lrr.2024.100490","url":null,"abstract":"<div><h3>Background</h3><div>Treatment of patients diagnosed with myelodysplastic neoplasms (MDS) is difficult and the outcome is still limited, especially in developing countries. We conducted this study in order to share some experience in treating patients diagnosed with MDS in developing countries.</div></div><div><h3>Methods</h3><div>This was a retrospective study that included 32 patients with newly MDS. 13 lower-risk patients, including 2 patients with MDS 5q- were treated with erythropoiesis stimulating agent (ESA). 19 patients with higher risk were treated with hypomethylating agent (HMA), which was decitabine.</div></div><div><h3>Results</h3><div>In the ESA treatment group, the rate of hematologic improvement-erythroid was 69.2 %, the rate of total hematologic improvement (with 3 lineages improvement) was 61.5 %. In the HMA treatment group, the overall response rate was 52.6 %. The follow-up times were 42 months. The overall survival (OS), leukemic transformation-free survival (LFS), and progression-free survival (PFS) of the ESA treatment group were 30.44, 28.91, and 28.29 months; respectively. The OS, LFS, and PFS of the HMA treatment group were 34.27, 31.45, and 26.83 months; respectively<strong>.</strong></div></div><div><h3>Conclusions</h3><div>Patients with lower risk MDS, including MDS 5q-, may benefit from treatment with erythropoiesis stimulating agent (ESA). Patients with higher risk MDS may have a favorable outcome with decitabine (HMA) treatment.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100490"},"PeriodicalIF":0.7,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Septic arthritis as breakthrough invasive fusariosis after cord blood transplantation 脐带血移植后作为突破性侵袭性镰刀菌病的化脓性关节炎

IF 0.7

Leukemia Research Reports Pub Date : 2024-01-01 DOI: 10.1016/j.lrr.2024.100483

Shinichi Katsuoka , Hidehiro Itonaga , Yasushi Sawayama , Masahiko Chiwata , Haruka Watanabe , Yuichi Yamada , Machiko Fujioka , Takeharu Kato , Shinya Sato , Koji Ando , Masato Tashiro , Takahiro Takazono , Yoshitaka Imaizumi , Koichi Izumikawa , Katsunori Yanagihara , Hiroshi Mukae , Yasushi Miyazaki

引用次数: 0

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in Jehovah's witness patients 治疗耶和华见证人患者中的费城染色体阳性急性淋巴细胞白血病

IF 0.7

Leukemia Research Reports Pub Date : 2024-01-01 DOI: 10.1016/j.lrr.2024.100474

Jeffrey Baron , Manu R. Pandey , Elizabeth A. Griffiths , Eunice S. Wang

引用次数: 0

Chronic myeloid leukemia with involvement of membranous labyrinth 慢性髓性白血病累及膜迷路

IF 0.7

Leukemia Research Reports Pub Date : 2024-01-01 DOI: 10.1016/j.lrr.2024.100471

Mobachir El Kettani , Kashish Shah , Hareem Farooq , Ke Li , Talha Badar

引用次数: 0

Real-world treatments and clinical outcomes in unfit AML patients receiving first-line treatment or best supportive care in Italy (CURRENT study) 意大利接受一线治疗或最佳支持治疗的不适合急性髓细胞白血病患者的实际治疗情况和临床结果（CURRENT 研究）

Leukemia Research Reports Pub Date : 2024-01-01 DOI: 10.1016/j.lrr.2024.100453

Maria Paola Martelli , Nicola Di Renzo , Antonio Curti , Nicola Stefano Fracchiolla , Luca Maurillo , Morena Caira , Paola Finsinger , Giuliana Gualberti , Felicetto Ferrara , Attilio Olivieri

引用次数: 0

A META-ANALYSIS OF COMPLICATED CASES OF INFLAMMATORY BOWEL DISEASE AND BONE MARROW FAILURE SYNDROME IN JAPAN 日本炎症性肠病和骨髓衰竭综合征复杂病例的荟萃分析

Leukemia Research Reports Pub Date : 2024-01-01 DOI: 10.1016/j.lrr.2024.100421

T. Yagi , H. Kumagai , A. Shimada

{"title":"A META-ANALYSIS OF COMPLICATED CASES OF INFLAMMATORY BOWEL DISEASE AND BONE MARROW FAILURE SYNDROME IN JAPAN","authors":"T. Yagi , H. Kumagai , A. Shimada","doi":"10.1016/j.lrr.2024.100421","DOIUrl":"https://doi.org/10.1016/j.lrr.2024.100421","url":null,"abstract":"<div><h3>Introduction</h3><p>Inflammatory bowel disease (IBD) is characterized by chronic inflammation within the digestive tract. In myelodysplastic syndrome (MDS) and aplastic anemia (AA), inflammation in the bone marrow is thought to be one of the causes. There are case reports of MDS or AA combined with IBD. Among these patients, there were several cases who improved hematopoietic function and IBD symptoms after treatment for MDS or AA. However, there are no summarized reports of cases of IBD combined with MDS or AA in Japan. We retrospectively reviewed the reports of IBD combined with MDS or AA in Japan.</p></div><div><h3>Methods</h3><p>We collected reports on cases of IBD combined with MDS or AA in Japan using Igaku Chuo Zasshi [Ichushi] and PubMed, and reviewed those cases.</p></div><div><h3>Results</h3><p>We collected 45 cases of IBD combined with MDS or AA. There were 28 and 19 cases of IBD combined with MDS and AA, respectively. Two cases progressed from AA to MDS. Seven cases occurred in the same period. In 21 cases, MDS or AA occurred prior to IBD. In 5 cases, hematopoietic stem cell transplantation restored both IBD and hematopoietic function.</p></div><div><h3>Conclusions</h3><p>We performed the first literature review of combined cases of IBD and MDS or AA in Japan. Considering the timing of onset and treatment response, there may be common pathologies in IBD and MDS or AA. However, we could not collect treatment details. We plan to construct a nationwide database of complicated cases and elucidate the pathophysiology of these cases.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100421"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000116/pdfft?md5=eed8f5705846a42368e187499e377e4d&pid=1-s2.0-S2213048924000116-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140103265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0